Wirth LJ, et al. Registrational results of LIBRETTO-001: A phase 1/2 trial of selpercatinib (LOXO-292) in patients with RET-altered thyroid cancers. ESMO Congress 2019. Abstract LBA93. 29 sept, Barcelona, Spanje.
TPEx versus EXTREME bij gerecidiveerd of gemetastaseerd hoofd-halscarcinoom
apr 2021 | Hoofd-halsoncologie